title: Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease.
abstract: Although regional cerebral metabolism and blood flow in Alzheimer's disease (AD) have been studied extensively with PET and SPECT, few reports have been concerned with cerebellar metabolism or perfusion in Alzheimer's disease. To evaluate cerebellar glucose metabolism in Alzheimer's disease patients, we studied the cerebellar and cerebral metabolic rate for glucose (CMRglc) using 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) and PET.
  
  
  METHODS
  Sixty-eight patients with Alzheimer's disease and 13 age-matched normal control subjects were examined. According to scores obtained on the Mini-Mental State Examination (MMSE), Alzheimer's disease patients were classified into three groups: severe (n = 9), moderate (n = 33) and mild (n = 26).
  
  
  RESULTS
  The cerebellar glucose metabolism in the severe Alzheimer's disease group was significantly lower (cerebellar glucose metabolism: 5.71 +/- 0.62 mg/100 g/min) than that of the control group (6.85 +/- 0.66 mg/100 g/min), while temporal and parietal CMRglc were much more decreased. The cerebellar glucose metabolism in the mild and moderate Alzheimer's disease groups also showed lower levels than that of the control group, but the differences did not reach significant levels. Like other cortical CMRglc, the cerebellar glucose metabolism correlated with cognitive impairments.
  
  
  CONCLUSIONS
  In severe Alzheimer's disease, cerebellar glucose metabolism is significantly reduced. The method of analysis using normalization of regional metabolic data to cerebellar values may be liable to err in severe Alzheimer's disease patients.
authors.affiliation: Division of Neuroimaging Research and Clinical Neurosciences, Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ishii
authors.forename: M
authors.initials: M
authors.lastname: Sasaki
authors.forename: H
authors.initials: H
authors.lastname: Kitagaki
authors.forename: S
authors.initials: S
authors.lastname: Yamaji
authors.forename: S
authors.initials: S
authors.lastname: Sakamoto
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: E
authors.initials: E
authors.lastname: Mori
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D016022:Case-Control Studies; D002531:Cerebellum / Q000000981:diagnostic imaging / Q000378:metabolism*; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D014055:Tomography, Emission-Computed
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; D005947:Glucose